Peptide API Manufacturing Reshoring Accelerates in 2026 as BIOSECURE Act Reshapes Supply Chain Strategy

Geopolitics Has Entered the Chemistry Lab

For most of the past two decades, the economic logic of peptide API sourcing was straightforward: manufacture in China or India, where labor costs are lower, infrastructure investment has been substantial, and the technical capability for large-scale peptide synthesis has been developed by companies including WuXi AppTec, ScinoPharm, Hybio Pharmaceutical, and Piramal Pharma Solutions, among others. This model produced reliable supply, competitive pricing, and reasonable quality and and it was the foundation on which much of the global peptide drug supply chain was built.

That model is now under structural pressure from multiple directions simultaneously, and the pharmaceutical industry is in the early stages of a reshoring transition that will reshape peptide manufacturing geography for decades.

The most significant regulatory driver is the BIOSECURE Act, signed into law in late 2024, which restricts U.S. federal agencies and federally funded programs from contracting with a specified list of Chinese biotechnology companies and and more broadly signals a legislative intent to reduce American pharmaceutical supply chain dependence on Chinese manufacturers. The Act's compliance timelines extend through 2032 for existing contracts, but its signaling effect has been immediate: pharmaceutical companies that anticipated the need to qualify domestic alternatives began the process well before any legal requirement triggered.

Simultaneously, the COVID-19 pandemic experience left a lasting imprint on pharmaceutical supply chain risk management philosophy. The disruptions of 2020-2022 and when API shortages created manufacturing bottlenecks for drugs that had nothing to do with COVID and demonstrated the systemic vulnerability of concentrated, geographically remote supply chains. For peptide APIs in particular, where manufacturing complexity limits the number of qualified suppliers globally, that concentration risk is especially acute.

By the numbers: A 2025 survey of pharmaceutical supply chain executives by a major consulting firm found that 74% had initiated formal reshoring or supply diversification assessments for peptide APIs, up from 31% in 2022. Among large-cap pharma companies, 89% reported having at least one active reshoring project for a commercially significant peptide compound.

The BIOSECURE Act: Specific Impacts on Peptide Supply Chains

The BIOSECURE Act's implications for peptide manufacturing are more specific and more immediate than its broad contours might suggest. Several of the named entities in the Act's restricted company list and including WuXi AppTec and its affiliates and are significant participants in the global peptide API manufacturing market, providing synthesis, purification, and fill-finish services for a substantial number of programs across the U.S. pharmaceutical industry.

Companies with existing supply relationships with named entities face a compliance clock. Programs in late clinical development or commercial launch that rely on a BIOSECURE-restricted supplier must either qualify an alternative source before the applicable compliance deadline or risk supply interruption. For drugs with established regulatory filings listing a specific manufacturer, the qualification of an alternative source requires a manufacturing supplement with the FDA and a process that, for complex peptide APIs, can take 18-30 months from initiation to approval.

This regulatory reality has created intense urgency around the qualification of alternative, compliant API sources and primarily domestic (U.S.) or allied-country (EU, Canada, Japan, Australia) manufacturers. The demand surge is real and immediate, and it is landing on a domestic manufacturing base that was not sized for it.

and Vice President, Global Supply Chain, Mid-Cap Pharmaceutical Company: "The BIOSECURE Act has done more to accelerate reshoring conversations than any supply chain strategy initiative we could have run internally. In six months, we went from 'this is a long-term risk to monitor' to 'this is an active project with a board-level timeline.' The urgency is unlike anything I've seen in 20 years of supply chain work"

Where the Investment Is Going: North America and Europe

The reshoring investment wave is geographically distributed across North America and Europe, with distinct patterns in each region.

United States. Federal incentives including the Bipartisan Infrastructure Law's pharmaceutical manufacturing provisions and targeted Department of Defense investments in domestic API manufacturing have catalyzed private investment. Thermo Fisher's $420 million Greenville, North Carolina expansion (announced March 2026) is explicitly framed around supply chain resilience for U.S. pharmaceutical customers. Recipharm's Niagara Falls facility and expanded with $180 million in investment announced in late 2025 and adds significant lyophilization and fill-finish capacity for peptide drug products. New entrants including Ajinomoto Bio-Pharma Services (AJB) are also expanding their U.S. footprint, leveraging parent company capabilities in amino acid chemistry and peptide synthesis.

Canada. The Canadian government's C$800 million strategic pharmaceutical manufacturing fund, established in 2024 and disbursing through 2027, has attracted several CDMO investments specifically targeting peptide API manufacturing. The favorable regulatory environment, English-language regulatory submissions, and geographic proximity to the U.S. market make Canada an attractive alternative to the continental U.S. for reshoring purposes.

Germany and Switzerland. European reshoring has concentrated in the traditional pharmaceutical manufacturing heartland of Germany, Switzerland, and Austria. Bachem's Sisseln campus expansion and Lonza's continued investment in Visp, both described in the context of broader CDMO capacity expansion, serve reshoring demand alongside the broader market growth. German chemical companies with peptide capabilities and including Evonik and Merck KGaA and have also made significant investments in GMP peptide synthesis infrastructure, supported in part by German federal and EU industrial policy frameworks.

Ireland. Ireland's position as a favored European manufacturing base for U.S. pharmaceutical companies has extended into the peptide API space. Several U.S.-headquartered pharmaceutical companies have invested in Irish manufacturing infrastructure specifically for peptide APIs, taking advantage of favorable corporate tax treatment, EU market access, and an existing skilled pharmaceutical manufacturing workforce.

By the numbers: North American peptide API manufacturing capacity is expected to grow from approximately 18% of global capacity in 2024 to an estimated 28% by 2029, based on announced investments and projected completion timelines and a significant geographic shift, though Asian manufacturers will continue to hold majority share through the decade.

The Cost Premium Reality

Reshoring has a price. Domestic peptide API manufacturing in North America and Western Europe carries a cost premium of approximately 35-65% over established Chinese manufacturers, depending on the compound, the scale, and the specific services required. This premium reflects higher labor costs, more expensive regulatory compliance infrastructure, higher energy costs in some locations, and the inherent inefficiencies of newer facilities that lack the process optimization accumulated over decades of operation.

For pharmaceutical companies that sourced peptide APIs from Chinese manufacturers primarily for cost reasons, this premium requires a fundamental repricing of their manufacturing economics. For drugs with thin margins and generic peptides, biosimilar analogs and the cost premium may be genuinely incompatible with commercial viability without government support or market pricing adjustments.

For innovative drugs with strong patent protection and premium pricing, however, the calculus is different. A 50% premium on manufacturing costs that represent 5-10% of the finished drug's revenue is commercially manageable and increasingly viewed as the price of supply security. For GLP-1 programs with multi-billion-dollar revenue potential, supply chain reliability is worth many multiples of the manufacturing cost differential.

The GMP compliance infrastructure costs are also higher for new domestic facilities simply because they must be built from scratch and qualified under current FDA and EMA standards and without the amortization benefit that established Asian facilities have achieved over decades of operation. CGMP documentation requirements for new facilities add additional upfront costs that are not reflected in steady-state per-kilogram pricing comparisons.

The Capacity Gap: The Critical 18-36 Month Window

The most significant near-term risk in the reshoring transition is the capacity gap and the period during which pharmaceutical companies have made the decision to qualify domestic suppliers but domestic capacity has not yet been validated and approved by regulators.

This gap is not hypothetical. It is the current reality for a significant number of programs. New CDMO capacity in North America and Europe that was announced in 2024 and 2025 will begin coming online between 2026 and 2028 and but the process of technology transfer, process validation, and regulatory submission and approval extends the timeline further. A pharmaceutical company that begins the reshoring process today may not have a fully approved domestic API source until 2028 or 2029, while its compliance obligation under the BIOSECURE Act requires transition by 2032 for many existing contracts.

The capacity gap creates several risks. For programs in active clinical development, API supply interruption during the gap period could delay trials and extend timelines to approval. For commercial products, supply interruption creates patient access risk and regulatory complications. Managing these risks requires maintaining compliant supply relationships in parallel with the qualification of new domestic sources and increasing cost and complexity during the transition period.

Environmental compliance considerations for new domestic facilities also add to startup timelines, as greenfield and brownfield manufacturing sites in North America and Europe must navigate permitting processes that can extend the pre-construction phase by 12-18 months.

The Workforce Dimension: Who Will Staff the Reshored Facilities?

The single most underappreciated constraint on reshoring timelines is workforce. Building a large-scale peptide API manufacturing facility in the American Southeast, the Canadian Prairies, or rural Germany is a capital and regulatory challenge and but it is also, fundamentally, a talent challenge.

Experienced peptide manufacturing personnel and process chemists who understand SPPS at commercial scale, analytical scientists with peptide API characterization expertise, QA/QC professionals with GMP documentation experience under FDA and EMA frameworks and are scarce. The existing U.S. and European peptide manufacturing workforce is already fully employed, largely by the CDMOs and pharmaceutical companies that have been operating in these geographies for years. The incremental hiring required to staff the reshored capacity represents a significant fraction of the currently available talent pool.

This creates a structural impediment: the announced capacity investments can only be operationalized as fast as qualified people can be hired, onboarded, and trained. Across the industry, workforce development leads are increasingly treating this as a multi-year pipeline problem rather than a near-term hiring exercise. University partnerships, co-op programs, community college technical training programs, and international recruitment are all being deployed to build the workforce pipeline that reshored manufacturing requires.

Outsourcing services and CDMO selection processes now frequently include workforce stability and hiring pipeline assessments and pharmaceutical company customers want assurance that their CDMO partner has the human capital to deliver on its capacity commitments, not just the physical infrastructure.

The regulatory compliance expertise required to navigate FDA and EMA submissions for new manufacturing sites also requires specialized personnel. Regulatory affairs scientists with peptide CMC experience, experienced with the specific requirements of peptide API filings, are among the most constrained resources in the entire reshoring ecosystem.

Conclusion: A Decade of Transition

The reshoring of peptide API manufacturing from Asia to North America and Europe is not a short-term trend and it is a decade-long structural transition that will reshape the industry's manufacturing geography, economics, and workforce composition through the 2030s. The BIOSECURE Act provided a regulatory trigger, but the underlying drivers and supply chain risk management, regulatory environment, quality assurance, and the strategic value of supply security for high-value drug products and will sustain the transition long after any specific legislative provision has been incorporated into standard industry practice.

The companies, CDMOs, and governments that invest now in the infrastructure, regulatory capability, and workforce development required to support domestic peptide manufacturing will be the ones best positioned when the transition matures. The cost premium of domestic manufacturing is real, but so is the cost of supply chain failure. As the industry has learned from the disruptions of the past decade, that latter cost is almost always larger than anyone anticipated and and almost always paid at the worst possible time.